TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07902245: A Randomized, Double-blind, Placebo-controlled, Single-Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of RG002C0106 Injection in Healthy Participants

Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,201,744

Rescue Site Savings

+$4,763,536

Unlock Full NCT07902245 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07902245 Rescue Dossier →